Benzamide, 4-(cyclopropylmethoxy)-3-methoxy-N-[2-(1H-1,2,4-triazol-1-yl)-5-(trifluoromethoxy)phenyl]-

Request For Quotation
Benzamide, 4-(cyclopropylmethoxy)-3-methoxy-N-[2-(1H-1,2,4-triazol-1-yl)-5-(trifluoromethoxy)phenyl]- Suppliers list
Company Name: Shanghai Beckham Medical Technology Co., Ltd  
Tel: 13816613772
Email: huahero21@sina.com
Company Name: Shanghai EFE Biological Technology Co., Ltd.  
Tel: 021-65675885 18964387627
Email: info@efebio.com
Company Name: Shanghai YuanYe Biotechnology Co., Ltd.  
Tel: 15026964105
Email: 2881489226@qq.com
Company Name: Shanghai Chaolan Chemical Technology Center  
Tel: QQ：65489617 13301690235
Email: Sales@ATKchemical.com
Company Name: MQ (shanghai) Pharmaceuticals Co., Ltd.  
Tel: 13761635123
Email: sales@linyuepharm.com

Benzamide, 4-(cyclopropylmethoxy)-3-methoxy-N-[2-(1H-1,2,4-triazol-1-yl)-5-(trifluoromethoxy)phenyl]- manufacturers

  • VU6012962
  • VU6012962 pictures
  • $43.00
  • 2026-07-14
  • CAS:2313526-86-0
  • Purity: 99.74%
  • Supply Ability: 10g
  • VU6012962
  • VU6012962 pictures
  • $43.00
  • 2026-07-14
  • CAS:2313526-86-0
  • Purity: 99.74%
  • Supply Ability: 10g
Benzamide, 4-(cyclopropylmethoxy)-3-methoxy-N-[2-(1H-1,2,4-triazol-1-yl)-5-(trifluoromethoxy)phenyl]- Basic information
Product Name:Benzamide, 4-(cyclopropylmethoxy)-3-methoxy-N-[2-(1H-1,2,4-triazol-1-yl)-5-(trifluoromethoxy)phenyl]-
Synonyms:Benzamide, 4-(cyclopropylmethoxy)-3-methoxy-N-[2-(1H-1,2,4-triazol-1-yl)-5-(trifluoromethoxy)phenyl]-;N-(2-(1H-1,2,4-Triazol-1-yl)-5-(trifluoromethoxy)phenyl)-4-(cyclopropylmethoxy)-3-methoxybenzamide;VU 6012962,Inhibitor,Metabotropic glutamate receptors,inhibit,mGluR,VU-6012962,VU6012962;VU6012962, 10 mM in DMSO
CAS:2313526-86-0
MF:C21H19F3N4O4
MW:448.4
EINECS:
Product Categories:
Mol File:2313526-86-0.mol
Benzamide, 4-(cyclopropylmethoxy)-3-methoxy-N-[2-(1H-1,2,4-triazol-1-yl)-5-(trifluoromethoxy)phenyl]- Structure
Benzamide, 4-(cyclopropylmethoxy)-3-methoxy-N-[2-(1H-1,2,4-triazol-1-yl)-5-(trifluoromethoxy)phenyl]- Chemical Properties
density 1.44±0.1 g/cm3(Predicted)
solubility DMSO:125.0(Max Conc. mg/mL);278.77(Max Conc. mM)
form Solid
pka11.79±0.70(Predicted)
color White to light yellow
Safety Information
MSDS Information
Benzamide, 4-(cyclopropylmethoxy)-3-methoxy-N-[2-(1H-1,2,4-triazol-1-yl)-5-(trifluoromethoxy)phenyl]- Usage And Synthesis
DescriptionVU6012962 is an orally bioavailable and CNS-penetrant metabotropic glutamate receptor 7 (mGlu7) negative allosteric modulator (NAM) that achieves exposure in cerebral spinal fluid (CSF) 2.5x above the in vitro IC50 at minimum effective doses (MEDs) of 3 mg/kg in preclinical anxiety models.
UsesVU6012962 is an orally bioavailable and CNS-penetrant metabotropic glutamate receptor 7 negative allosteric modulator (mGlu7 NAM) with an IC50 of 347 nM[1].
in vitroAs many mGlu allosteric ligands engage induced-fit pockets, SAR can be challenging, and the “right” fit may only be “found” by exploring libraries of analogs via an exercise in strategic serendipity. VU6012962 (7d) proved optimal (IC50 = 350 nM, pIC50 = 6.46 ± 0.10, 12.6 ± 1.5% L-AP4 min) and the most potent within this chemotype to date. Beyond an enhancement in mGlu7 NAM potency, 7d also showed a significant improvement in predicted hepatic clearance (rat CLhep = 15.9 mL min–1 kg–1), generating enthusiasm for the further profiling of 7d. 7d was selective for mGlu7 versus the other seven mGlu receptors (>10 μM versus mGlu1–6,8) and largely devoid of ancillary pharmacology (compound activity at only one target, 5-HT2B receptor, that was greater than 50% at 10 μM) in a Eurofins lead profiling panel of 68 GPCRs, ion channels, and transporters. A 30 mg/kg (ip) tissue distribution study in rat was performed to assess levels of 7d in plasma, brain, and CSF. Here, it was noted that a brain:plasma Kp of 1.24 (([plasma]tot = 598 nM), [brain]tot = 745 nM) and a Kp,uu of 0.38 ([plasma]Unbound = 16.7 nM, [brain]unbound = 6.4 nM); however, the CSF:plasma Kp was 2.15, with levels of 7d in CSF of 1.3 μM, or ~3.8-fold above the in vitro IC50._x000D_ _x000D_ Reference: J Med Chem. 2019 Feb 14;62(3):1690-1695. https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/30608678/
in vivo

VU6012962 (1-10 mg/kg; i.p. injection; 60 minutes prior to testing) decreases anxiety in the elevated zero maze (EZM) assay in mice[1].

Animal Model:C57Bl/6J male mice (8 weeks old)[1]
Dosage:1, 3, and 10 mg/kg
Administration:I.p. injections; 60 minutes prior to testing
Result:Increased total time spent in the open arms at a dose of 3 mg/kg. 10 mg/kg did cause a decrease in overall locomotion.
targetVU6012962 is an orally bioavailable and CNS-penetrant metabotropic glutamate receptor 7 negative allosteric modulator (mGlu7 NAM) with an IC50 of 347 nM.
IC 50mGlu7: 347 nM (IC50)
References[1] Reed CW, et al. Discovery of an orally bioavailable and Central Nervous System (CNS) penetrant mGlu7 NegativeAllosteric Modulator (NAM) in vivo tool compound: N-(2-(1H-1,2,4-triazol-1-yl)-5-(trifluoromethoxy)phenyl)-4-(cyclopropylmethoxy)-3-methoxybenzamide (VU6012962). J Med Chem. 2019 Jan 4. DOI:10.1021/acs.jmedchem.8b01810
Benzamide, 4-(cyclopropylmethoxy)-3-methoxy-N-[2-(1H-1,2,4-triazol-1-yl)-5-(trifluoromethoxy)phenyl]- Preparation Products And Raw materials
Tag:Benzamide, 4-(cyclopropylmethoxy)-3-methoxy-N-[2-(1H-1,2,4-triazol-1-yl)-5-(trifluoromethoxy)phenyl]-(2313526-86-0) Related Product Information
N-(4-Methyl-2-thiazolyl)-2-[(6-phenyl-3-pyridazinyl)thio]acetamide VU6005806 N-[1-(2-Fluorophenyl)-3-phenyl-1H-pyrazol-5-yl]-4-nitrobenzamide VU6010608 Benzamide, 4-fluoro-3-[[[5-(1-methyl-1H-pyrazol-3-yl)-3-pyridinyl]methyl]amino]-N-[3-(trifluoromethoxy)phenyl]- Thieno[2,3-c]pyridazine-6-carboxamide, 5-amino-N-[1-(2,3-difluorophenyl)-3-azetidinyl]-3,4-dimethyl- VU6005649 VU6001221